RETROSPECTIVE STUDY ON TRILOSTANE TITRATION DOSE TREATMENT IN DOGS WITH TERMINAL STAGE OF HYPERADRENOCORTICISM
Journal
Macedonian Veterinary Review
Date Issued
2024-02-28
Author(s)
Irena Celeska
Martin Nikolovski
Todor Novakov
Anastasija Angelovska
Ivica Gjurovski
Elena Atanaskova Petrov
DOI
https://doi.org/10.2478/macvetrev-2024-0016
Abstract
Hyperadrenocorticism (HAC) in dogs is routinely treated with trilostane single-dose (CTG) which is reported to
cause adverse reactions. The current retrospective study of several dogs with terminal stage of HAC aimed to compare the
clinical, hematological, and biochemical effects of trilostane titration-dose treatment (TTG) with the single-dose treatment
(CTG). All clinical cases (n=7) were confirmed on HAC by anamnestic, clinical, hematology, biochemistry, and low-dose
dexamethasone suppression test findings, indicative for Cushing’s disease. Two cases were treated with CTG (2.2-6.7 mg/kg,
single dose daily) and their treatment was discontinued on the second week due to adverse reactions. The TTG cases were
treated for up to 12 weeks (0.5 mg/kg once daily for 7 days, and then with 0.5 mg/kg twice daily for 7 days). Blood samples
and clinical checks were performed on 0., 4., and 12. weeks of the treatment. Hemoglobin was non-significantly higher in TTG
at 12 weeks. Alanine transaminase was significantly lower in the TTG cases on the 12. week of the treatment (78.04±15.37 U/L)
compared to the 0-week (137.81±24.03 U/L), and 4-week samples (131.92±23.36 U/L). No significant differences were
observed with the CTG cases. Alkaline phosphatase was significantly lower on 12-week samples in TTG (251.02±93.06)
compared to the 4-week (567.94±283.93 U/L), and 0-week samples (1,341.84 U/L). In conclusion, TTG has indicated to have
significantly higher tendency to decrease alanine transaminase and alkaline phosphatase, alleviating the negative effects on
the liver. The clinical findings were more adverse for the CTG.
cause adverse reactions. The current retrospective study of several dogs with terminal stage of HAC aimed to compare the
clinical, hematological, and biochemical effects of trilostane titration-dose treatment (TTG) with the single-dose treatment
(CTG). All clinical cases (n=7) were confirmed on HAC by anamnestic, clinical, hematology, biochemistry, and low-dose
dexamethasone suppression test findings, indicative for Cushing’s disease. Two cases were treated with CTG (2.2-6.7 mg/kg,
single dose daily) and their treatment was discontinued on the second week due to adverse reactions. The TTG cases were
treated for up to 12 weeks (0.5 mg/kg once daily for 7 days, and then with 0.5 mg/kg twice daily for 7 days). Blood samples
and clinical checks were performed on 0., 4., and 12. weeks of the treatment. Hemoglobin was non-significantly higher in TTG
at 12 weeks. Alanine transaminase was significantly lower in the TTG cases on the 12. week of the treatment (78.04±15.37 U/L)
compared to the 0-week (137.81±24.03 U/L), and 4-week samples (131.92±23.36 U/L). No significant differences were
observed with the CTG cases. Alkaline phosphatase was significantly lower on 12-week samples in TTG (251.02±93.06)
compared to the 4-week (567.94±283.93 U/L), and 0-week samples (1,341.84 U/L). In conclusion, TTG has indicated to have
significantly higher tendency to decrease alanine transaminase and alkaline phosphatase, alleviating the negative effects on
the liver. The clinical findings were more adverse for the CTG.
Subjects
File(s)![Thumbnail Image]()
Loading...
Name
macvetrev-2024-0016.pdf
Description
RETROSPECTIVE STUDY ON TRILOSTANE TITRATION DOSE TREATMENT IN DOGS WITH TERMINAL STAGE OF HYPERADRENOCORTICISM
Size
323.32 KB
Format
Adobe PDF
Checksum
(MD5):41c0f8ebb2b256f8b874046d2c3139bd